Marco Mottinelli

Marco Mottinelli

Assistant Scientist

Department: Medicinal Chemistry
Business Phone: (352) 273-7714
Business Email:

About Marco Mottinelli

Marco Mottinelli received his master’s degree in Chemistry and Pharmaceutical Technology at the University of Pisa, Italy. After graduating, he spent one year at DSM pharmaceutical products, the Netherlands, before moving to the University of Bath, England to pursue his Doctorate degree in medicinal chemistry. Upon completion of his Ph.D. on the synthesis and biological evaluation of novel chemical entities targeting estrogen biosynthesis and signaling for the treatment of breast cancer, Mottinelli moved to the University of Mississippi as a postdoctoral associate within the group of Dr. Christopher McCurdy. In 2017, Dr. Mottinelli joined the University of Florida as a postdoctoral research associate in the department of Medicinal Chemistry and in 2020 he obtained the Research Assistant position. His research focuses on the development of neurotherapeutics in the areas of pain and drug of abuse and more specifically on Neuropeptide FF receptor and Sigma receptors ligands.


N-Phenyl-1,2,3,4-tetrahydroisoquinoline: An Alternative Scaffold for the Design of 17β-Hydroxysteroid Dehydrogenase 1 Inhibitors.
ChemMedChem. 16(1):259-291 [DOI] 10.1002/cmdc.202000762. [PMID] 33151004.
Pharmacological Comparison of Mitragynine and 7-Hydroxymitragynine: In Vitro Affinity and Efficacy for Mu-Opioid Receptor and Opioid-Like Behavioral Effects in Rats.
The Journal of pharmacology and experimental therapeutics. [DOI] 10.1124/jpet.120.000189. [PMID] 33384303.
Evaluation of 18F-IAM6067 as a sigma-1 receptor PET tracer for neurodegeneration in vivo in rodents and in human tissue.
Theranostics. 10(18):7938-7955 [DOI] 10.7150/thno.47585. [PMID] 32724451.
Divergent Cytotoxic and Metabolically Stimulative Functions of Sigma-2 Receptors: Structure-Activity Relationships of 6-Acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79) Derivatives.
The Journal of pharmacology and experimental therapeutics. 368(2):272-281 [DOI] 10.1124/jpet.118.253484. [PMID] 30530624.
Characterization of Sigma 1 Receptor Antagonist CM-304 and Its Analog, AZ-66: Novel Therapeutics Against Allodynia and Induced Pain.
Frontiers in pharmacology. 10 [DOI] 10.3389/fphar.2019.00678. [PMID] 31258480.
Bioanalytical method development and validation of MES207, a neuropeptide FF receptor antagonist, and its application in preclinical pharmacokinetics.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 1134-1135 [DOI] 10.1016/j.jchromb.2019.121875. [PMID] 31790916.
Accessing simply-substituted 4-hydroxytetrahydroisoquinolines via Pomeranz-Fritsch-Bobbitt reaction with non-activated and moderately-activated systems.
Beilstein journal of organic chemistry. 13:1871-1878 [DOI] 10.3762/bjoc.13.182. [PMID] 29062406.
Synthesis of sulfonamide-containing N-hydroxyindole-2-carboxylates as inhibitors of human lactate dehydrogenase-isoform 5.
Bioorganic & medicinal chemistry letters. 21(24):7331-6 [DOI] 10.1016/j.bmcl.2011.10.031. [PMID] 22056743.

Teaching Profile

Courses Taught
PHA6447 Drug Design

Contact Details

(352) 273-7714